Relapsed Chronic Lymphocytic Leukemia
Oncology·MeSH: Lymphoma, Follicular
Prevalence
20.0 / 100K
Incidence
4.7 / 100K/yr
3 drugs in development·3 companies·3 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| zydelig | GILEAD SCIENCES, INC. (GILD) |
Phase 3(1)
| Drug | Company |
|---|---|
| Roginolisib | ENANTA PHARMACEUTICALS INC (ENTA) |
Phase 1(1)
| Drug | Company |
|---|---|
| BP1002 | BIO-PATH HOLDINGS, INC. (BPTH) |
Compare drugs
Frequently asked questions
How many drugs are in development for Relapsed Chronic Lymphocytic Leukemia?
BioSniper tracks 3 drugs in development for Relapsed Chronic Lymphocytic Leukemia across 3 companies.
How many clinical trials target Relapsed Chronic Lymphocytic Leukemia?
There are 3 clinical trials targeting Relapsed Chronic Lymphocytic Leukemia tracked by BioSniper.
What is the prevalence of Relapsed Chronic Lymphocytic Leukemia?
The estimated prevalence of Relapsed Chronic Lymphocytic Leukemia is approximately 20.0 per 100,000 population.
Deep-dive into Relapsed Chronic Lymphocytic Leukemia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis